Skip to main content

MSCopilot - Digital Assessment in Multiple Sclerosis

What is MS?

Multiple Sclerosis is a chronic autoimmune disease, which attacks myelin - the substance that surrounds and insulates the nerve fibers — as well as the nerve fibers themselves.

MS impacts patients' motricity, balance, vision and evolves by relapses. In 85% of cases, patients develop handicaps and a loss of motricity.

More than 2.5 million people worldwide are affected by MS. Its treatment costs are estimated between 15 and 20 billion euros per year in Europe. Currently, the means used to follow and treat MS are not optimized. The patient assessment relies on a score coming from medical gold standards tests / questionnaires (MSFC, EDSS...) hard and lengthy to conduct and presenting several limits.

 

MSCopilot, an innovation in MS assessment

Ad Scientiam has developed MSCopilot, which innovates in MS self-assessment and aims at becoming THE new market standard.

In addition, several digital functionalities will support patients (symptom checker, adherence, tutorials...)

Self-assessment tests developed were built from the MSFC method, co-created with a board of experts and patients, and validated through large scale clinical trial. They will evaluate vision, cognition, dexterity and walking.

Finally, collected real-world data will allow future analytics studies and continuous improvement of algorithms.

 

This program has been conducted with the institutional support of Roche France, a medical board of neurologists and leading patients and clinicians associations (French Federation of Neurology, OFSEP, ARSEP)

A Proof-of-Concept study was conducted in 2016 on MSCopilot (TRL 6: System/subsystem model or prototype demonstration in a relevant environment), demonstrating a strong correlation between MSCopilot and MSFC scores.

 

MSCopilot® was supported by the french program investissement d'avenir

Ad Scientiam has just started the AI Factory for Health, a three months acceleration program to empower top AI startups to solve today's health...

A new partnership has been signed between WeHealth Digital Medicine and Ad Scientiam to develop a mobile health app which integrates physical...

Ad Scientiam and Biogen have entered into a scientific collaboration to develop innovative digital solutions for clinical research in neurosciences....

Let's go back on the 9 months we spent with Pfizer Healthcare Hub, and all the help they gave us through this partnership.

Read the article (in...

Liouma Tokitsu, CEO and founder of Ad Scientiam, was at the Microsoft Envision The Tour, a conference hosted by Microsoft and presented by Carlo...

MSCopilot, the new multiple sclerosis self-assessment digital solution developed by AdScientiam, has been clinically validated in a clinical trial...


The month of June ended under international spotlights at the 5th European Academy of Neurology Congress at Oslo, where Dr Elisabeth Maillart...

The #MyInvisibleMS” campaign for the 2019 World MS Day aims to alert the general public to the MS invisible symptoms and their impacts on the quality...

On 16th Thursday and 17h Friday our glorious team was at Vivatech, the world’s rendezvous for startups and leaders to celebrate innovation !

Ad...

Dr Yann le Coz is a medical doctor and a MS patient. As a volunteer he brings his expertise to the development of MSCopilot®. In this video shot by...